All Supplements
    Supplement

    TUDCA (Tauroursodeoxycholic Acid)New

    Supplement
    Longevity Compounds
    5/10 Evidence

    Tauroursodeoxycholic acid (TUDCA) is a taurine-conjugated bile acid long used clinically (as the closely related ursodeoxycholic acid) for cholestatic liver disease and gallstone dissolution, and separately studied as a molecular chaperone that reduces endoplasmic reticulum (ER) stress. A small human RCT (Kars et al., Diabetes, 2010) found TUDCA improved hepatic and muscle insulin sensitivity in obese, insulin-resistant adults. Interest in TUDCA's neuroprotective potential grew after the taurursodiol-containing ALS drug AMX0035 (Relyvrio) showed benefit in its Phase 2 CENTAUR trial and won FDA approval in 2023 — but its confirmatory Phase 3 PHOENIX trial failed in 2024, and the drug was voluntarily withdrawn from the market, a cautionary example of how promising early signals in this compound class have not always replicated.

    Mechanism of Action

    As a hydrophilic bile acid, TUDCA displaces more toxic hydrophobic bile acids in the liver and biliary tree, protecting hepatocytes and improving bile flow. Independent of its bile-acid activity, TUDCA acts as a chemical chaperone that stabilizes protein folding in the endoplasmic reticulum, reducing ER-stress-induced apoptosis — a pathway implicated in insulin resistance, hepatic steatosis, and several neurodegenerative processes. This dual liver-protective and chaperone activity is the basis for its use in cholestatic liver disease and its investigational use in metabolic and neurodegenerative conditions, though the chaperone mechanism has translated to a confirmed human clinical benefit far more consistently in liver and metabolic endpoints than in neurodegeneration.

    Dosing Protocol

    Recommended

    250mg two to three times dailymg

    Standard starting dose based on research

    Therapeutic Range

    250

    Minimum

    to

    1500

    Maximum

    mg

    With meals, divided doses

    Dosages are general guidelines. Individual requirements vary based on body weight, health status, and specific goals. Start with lower doses and adjust based on response.

    Benefits

    Primary Benefits

    • Liver support
    • Bile flow / cholestasis
    • Insulin sensitivity
    • Cellular stress protection

    Secondary Benefits

    ER stress reduction
    Neuroprotection (investigational)

    Safety Information

    Contraindications

    Do not use if any of the following apply:

    • Biliary obstruction
    • Acute gallstone disease
    • Pregnancy (insufficient data)

    Drug/Supplement Interactions

    May interact with the following. Consult a healthcare provider before combining:

    Bile acid sequestrants (cholestyramine)
    Fat-soluble vitamin absorption

    Potential Side Effects

    Some users may experience:

    GI upset
    Diarrhea
    Loose stools at higher doses

    This is not a complete list of interactions or side effects. Individual responses vary. Always start with the lowest effective dose and monitor your response. Report any adverse effects to your healthcare provider.

    Quality Markers

    Look for these specific quality indicators when sourcing this compound:

    • Third-party tested for purity
    • Pharmaceutical-grade synthesis (not animal bile-derived)
    • Verified TUDCA content (not diluted with UDCA)

    Trusted Certifications

    NSF Certified
    USP Verified
    GMP Certified
    ConsumerLab Approved

    Note: Supplement quality varies dramatically between brands. Cheap supplements often contain fillers, incorrect doses, or contaminants. Investing in quality products from reputable manufacturers is essential for safety and efficacy.

    Evidence Profile

    Evidence Score

    5/10

    Moderate Evidence

    Some clinical trials with positive results, emerging research

    Classification:
    Moderate for liver and insulin-sensitivity endpoints (supported by clinical use of the related bile acid UDCA and a positive human RCT on insulin sensitivity); evidence for neuroprotective or longevity benefits is weak and cautionary — the related ALS drug AMX0035 (Relyvrio) failed its Phase 3 confirmatory trial in 2024 and was withdrawn from the market despite an earlier positive Phase 2 result. Evidence

    Evidence Scale

    8-10

    Strong

    5-7

    Moderate

    1-4

    Emerging

    PHS
    671
    / 1000
    T3
    Longevity Operator

    Sample member

    Longevity Operator

    The Peak Human Score · PHS v1

    One number for your longevity journey.

    FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.

    • Metabolic
    • Hormonal
    • Cardiovascular
    • Brain / Cognitive
    • Sleep
    • Musculoskeletal
    • Gut
    • Immunity / Inflammation